In this episode, we discuss the new FDA categorizations of biosimilars, the legal implications of biologic/biosimilar prescriptions, and the new "follow-on" approval pathway of Basaglar, a new insulin glargine U-100 product.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast","authorlink":""},"src":"https:\/\/traffic.libsyn.com\/secure\/helixtalk\/056_-_Biosimilars.mp3?dest-id=187168","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202310\/51d8ce-5810-087d-300941_800.png"},"title":"056 - Entering the era of biosimilars!","link":"javascript:;","id":"item-685449"}]
